Panel Discussion: Balancing Differentiation, Combination Strategies & Commercial Reality to Define the Next Generation of Successful MASH Therapies
- Evaluating how developers can differentiate new therapies within an increasingly competitive landscape to demonstrate meaningful clinical value, enabling stronger positioning and improving future adoption
- Assessing when combination approaches are likely to provide the greatest therapeutic advantage over monotherapy strategies, improving development prioritization and maximizing long-term patient benefit
- Defining the clinical, regulatory and commercial attributes required for future therapies to succeed beyond initial approval, strengthening development decision-making and supporting long-term market impact